Patent ID: 6908911

Claim:
A method of treating bacterial infections in humans and non-human mammals comprising administering an antibacterially effective amount of a compound selected from the group consisting of N-[3S-(4-benzylpiperidine-1-carbonyl)-2,2-dimethyl-propyl]-3-cyclopentyl-2R[(formyl-hydroxy-amino)-methyl]-propionamide, N-[2R-(4-benzyl-piperidine-1-carbonyl)-hexyl]-N-hydroxy-formamide, N-hydroxy-N-[2R-(2-methyl-piperidine-1-carbonyl)-hexyl]-formamide, N-hydroxy-N-[2R-(piperidine-1-carbonyl)-hexyl]-formamide, N-hydroxy-N-[2R-(piperazine-1-carbonyl)-hexyl]-formamide, 2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid pyrrolidin-1-ylamide, 2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid methyl-(1-methylpiperidin-4-yl)-amide, N-[2R-(azepane-1-carbonyl)-hexyl]-N-hydroxy-formamide, 2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid (4-methyl-piperazin-1-yl)-amide, 2R-[(formyl-hydroxy-amino)-methy]-hexanoic acid diisopropylamide, 1-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-piperidine-3-carboxylic acid ethyl ester, 4-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-piperazine-1-carboxylic acid ethyl ester, 4-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoyl}-1,1-dimethyl-piperazinium iodide, 2R-[(Formyl-hydroxy-amino)-methyl]-hexanoic acid [2,2-dimethyl-1 (piperidine-1-carbonyl)-propyl]-amide, 2R-[(formyl-hydroxy-amino)-methyl]-hexanoicacid [1S-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-2,2-dimethyl-propyl]-amide, 2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [1S-(4-benzyl-4-hydroxy-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide, 2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [1S-(4-benzyl-piperazine-1-carbonyl)-2,2-dimethyl-propyl]-amide, 2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid (3-benzylsulfanyl-1S-dimethylcarbamoyl-propyl)-amide, 3S-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoylamino}-N,N-dimethyl-succinamic acid benzyl ester, 4S-dimethylcarbamoyl-4-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoyamino-butyric acid benzyl ester, (5S-dimethylcarbamoyl-5-{2R-[(formyl-hydroxy-amino)-methyl]-hexanoylamino}-pentyl)-dimethyl-ammonium chloride, 2R-[(formyl-hydroxy-amino)-methyl]-butyric acid (1-carbamoyl-2,2-dimethylpropyl)amide, 2-[(formyl-hydroxy-amino)-methyl]-hexanoic acid (1-carbamoyl-2,2-dimethylpropyl)amide, 2R-[formyl-hydroxy-amino)-methyl]-hexanoic acid (1-dimethyl-carbamoyl-4-guanidinobutyl)-amide, 2R-[2-(4-chlorophenyl)-3-(formyl-hydroxy-amino)-propionylamino]-2S-3,3,N,N-tetramethyl-butyramide, 2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [2(3,4-dihydroxy-phenyl)-ethyl]-amide, 2R-[(formyl-hydroxy-amino)-methyl]-hexanoic acid [2(4-hydroxyphenyl)-ethyl]-amide, or pharmaceutically and veterinarily acceptable salts, hydrates or solvates thereof.